Galderma secured CE marking for Restylane Shaype for chin augmentation, broadening the product's indication set beyond its original lip-enhancement positioning. The approval signals confidence in the filler's rheology and safety profile for structural facial support in a region that demands both projection and natural contour.
Injectables
Galderma Wins EU Nod for Restylane Shaype
CE mark granted for chin augmentation indication; expands Restylane portfolio beyond lips.

1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |